SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- LinkedIn’s Growth Is Already Priced In: Analyst

TOP HEADLINES

» Markets | Economy | Companies

- With Many Investors So Bullish, Stock Pullback Must Be Ahead

PHARMA'S MARKET VIDEO

» More

Wall Street Protests 29 Apr 2010
Following a big demonstration in favor of financial regulation right outside the NYSE, with CNBC's Mike Huckman.
March on Wall Street 29 Apr 2010
Main Street takes to Wall Street today with thousands of union community activists marching to make the big banks pay, with CNBC's Mike Huckman.
Mike Huckman: Reporter's Reporter 29 Apr 2010
Original air date, June 26, 2002.
SBUX Beats the Street 21 Apr 2010
CNBC's Mike Huckman has Starbucks' earnings breakdown.

The Orange Squeeze on Dimon

16 Apr 2010

Some students at Syracuse University have a different idea rather than having JPMorgan's chairman/CEO Jamie Dimon deliver this year's commencement speech, reports CNBC's Mike Huckman.

Nasdaq Outperforms 14 Apr 2010
The Nasdaq easily outperforming the other major indexes today, with CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

Pharma's Market

Text Size

Dec.19

3:14 PM ET

Friday, 19 Dec 2008

Vertex's $75,000 Question

Posted By:Mike Huckman

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Genentech, Inc. | Vertex Pharmaceuticals Incorporated | Johnson and Johnson | Schering Plough Corp

Drug pricing pressure under a Democratic administration be darned. $75,000.

That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson [JNJ Loading... () ] might be able to charge--possibly even more--for their Hepatitis C drug.

Shares of VRTX [VRTX Loading... () ] appear to be rallying on that call.

In a research note to clients Bernstein's Geoffrey Porges says after doing a detailed pharmacoeconomic (boy, is that a mouthful) analysis he estimates the companies could charge as much as 75-grand per course.

The drug is in late-stage development. VRTX and JNJ are in a race with Schering-Plough [SGP Loading... () ] to bring a new Hep-C drug to market. Currently available drugs don't work on a lot of patients and even if they do work they make some people feel so sick they can't stay on them. So, there's a big unmet medical need and untapped drug market here.

The $75,000 estimate is $35,000 higher than Porges' previously increased calculation. He's basing the bullish pricing forecast on newer scientific evidence about how well the drug appears to work.

But he cushions the number a bit by writing, "Our model suggests that Vertex could still make a cost effectiveness argument in favor of telaprevir (that's the name of the drug) up to or above $75,000 per patient, though we think it is highly unlikely Vertex will price (it) that high."

A Vertex spokesman says, "We simply do not comment on price at this stage in development."

Vertex is often on the list of usual suspects of biotechs that could be bought.

Bernstein makes a market in VRTX. And someone in Porges' family owns VRTX stock.

Last August Porges predicted Roche might pay as much as $130 a share for Genentech [DNA Loading... () ], but that was before the credit crisis hit and the markets tanked.